MRD: 2/22/07

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Pagerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute f	or form 1449A	/PTO		Complete if Known				
MEG	354 A TIG			Application Number	10/088,138			
	_	-	CLOSURE	Filing Date	11-25-2002			
STAT	EMENT	BY AF	PLICANT	First Named Inventor	MOUSSAOUI-MRABET			
				Group Art Unit	1632			
(u	se as many :	sheets as n	ecessary)	Examiner Name	FALK, Anne Marie			
Sheet	1	of	4	Attorney Docket Number	ST99040 - US - PCT			

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Paten Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Possages or Rolovant Figures Appear			
/AME/		6,734,336		Scott et al.	05-11-2004				
			<u> </u>						
	· <u> </u>			- · · · · · · · · · · · · · · · · · · ·	 				

		<u></u>							
					<u> </u>				
 -∤									
	-								
				•					
					 	······			

FOREIGN PATENT DOCUMENTS									
	C 4-		Foreign Patent Do	ocument	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	Т	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т	
/AMF/		wo	02/08407		CEPHALON INC.	01-31-2002			
							*.		
								╀	
						+		╁	
						 		+	
								1	
					-			T	

Examiner Date Date	
= Name	
Signature /Anne Marie Falk/ Considered 07/23/2007	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Please type	a	plus sign	(+)	inside	this	box	→	V
-------------	---	-----------	-----	--------	------	-----	----------	---

Substitute for form 1449B/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

PTO/SB/088 (10-96)

Approved for use through 10/31/99, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Complete if Known					
Application Number	10/088,138				
Filing Date	11-25-2002				
First Named Inventor	MOUSSAOUI-MRABET				
Group Art Unit	1632				
Examiner Name	FALK, Anne Marie				
Attorney Docket Number	ST99040 - US - PCT				

	·	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials' Cite No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
		BORCHELT et al., Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins, Neuron, Vol. 19, Oct. 1997, pp. 939-945	
		CAMPION, Dominique et al., A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years, NeuroReport, (1996), Vol. 7, pp. 1582 - 1584	
		CHEN et al., Neurodegenerative Alzheimer-like pathology in PDAPP 717V-F transgenic mice, Progr. Br. Res. Vol. 117, 1998, pp. 327-334	
		CHUI et al., Transgenic mice with Alzhelmer presenilin 1 mutations show accelerated meurodegeneration without amyloid plaque formation, Nature Medicine, Vol. 5, No. 5, May 1999, pp. 560-564	
		CZECH et al., Characterization of Human Presenilin 1 Transgenic Rats: Increased Sensitivity To Apoptosis in Primary Neuronal Cultures, Neuroscience, Vol. 87, No. 2, pp. 325-336, 1998	
		CZECH et al., Proteolytical processing of mutated human amyloid precursor protein in transgenic mice, Mol. Br. Res. Vol. 47, 1997, pp. 108-116	
		GUO et al., Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid Beta-peptide, Neuroreport, Vol. 8, No. 1, Dec.1996, pp. 379-383	
	- 1	GUO et al., Alzheimer's Presenilin Mutation Sensitizes Neural Cells to Apoptosis Induced by Trophic Factor Withdrawal and Amyloid Beta-Peptide: Involvement of Calcium and Oxyradicals, J. Of Neuroscience, Vol. 17, No. 11, June, 1997, pp. 4212-4222	
		HOLCOMB et al., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nature Medicine, Vol. 4, No. 1., Jan. 1998, pp. 97-100	
AMF/		HSIAO et al., Correlative Memory Deficits, ABeta Elevation, and Amyloid Plaques in Transgenic Mice, Science, Vol. 274, 1996, pp. 99-102	

Date Considered	07/23/2007
	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Please type a	plus sign (+) inside this box 🛶	

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.


Substitu	ute for form 1449B/PT	0		Complete if Known			
	001147101			Application Number	10/088,138		
INF	OKMATIOI	4 L	DISCLOSURE	Filing Date	11-25-2002		
STATEMENT BY APPLICANT				First Named Inventor	MOUSSAOUI-MRABET		
				Group Art Unit	1632		
	(use as many s	sheet	's as necessary)	Examiner Name	FALK, Anne Marie		
heet	3	of	4	Attorney Docket Number	ST99040 - US - PCT		

	r—	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
		IRIZARRY et al., A Beta Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPPO Transgenic Mouse, J. of Neuroscience, Sept. 15, 1997, Vol. 17, No. 18, pp. 7053-7059	
		IRIZARRY et al., APPsw Transgenic Mice Develop Age-related Abeta Deposits and Neuropil Abormalities, but no Neuronal Loss in CA1, J. of Neuropathology and Experimental Neurology, Vol. 56, No. 9, Sept. 1997, pp. 965-973	
		JOHNSON-WOOD et al., Amyloid precursor protein processing and A Beta42 deposition in a transgenic mouse model of Alzheimer disease, PNAS, Vol. 94, Feb. 1997, pp. 1550-1555	
		LEUTNER et al., Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations, Neuroscience Letters, Vol. 292, 2000, pp. 87-90	
		MASLIAH et al., Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-Amyloid Precursor Protein and Alzheimer's Disease, J. of Neuroscience, Sept. 15, 1998, Vol. 16, No.18, pp. 5795-5811	
		MOECHARS et al., Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein In Brain, J. of Biol. Chem., Vol. 274, No. 10, March 5, 1999, pp.6483-6492	
		MOECHARS et al., Premature Death in Transgenic Mice That Overexpress A Mutant Amyloid Precursor Protein is Preceded By Severe Neurodegeneration And Apoptosis, Neuroscience, Vol. 91, No. 3, 1999, pp. 819-830	
		MOECHARS et al., Transgenic mice expressing an alpha-secretion mutant of the amyloid precursor protein in the brain develop a progressive CNS disorder, Behavioural Brain Res., Vol. 95, 1998, pp. 55-64	
		PAPPOLLA et al., Evidence of Oxidative Stress and in Vivo Neurotoxicity of Beta-Amyloid in a Transgenic Mouse Model of Atzheimer's Disease, Am. J. or Pathology, Vol. 152, No. 4, April 1998, pp. 871-877	
AMF/		PRICE et al., Mutant Genes In Familial Alzheimer's Disease And Transgenic Models, Annu. Rev. Neurosci. 1998, Vol. 21, pp. 479-505	

Examiner Signature	/Anne Marie Falk/	Date Considered	07/23/2007

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box 🛶 🗸	7
---	---

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/088,138	
				Filing Date	11-25-2002	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	MOUSSAOUI-MRABET	
				Group Art Unit	1632	
(use as many sheets as necessary)			s necessary)	Examiner Name	FALK, Anne Marie	
Sheet	4	of	4	Attorney Docket Number	ST99040 - US - PCT	

	,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1					
/AMF/		ROCKENSTEIN et al., Early Formations of Mature Amylold-Beta Protein Deposits in a Mutant APP Transgenic Model Depends on Levels of AlphaBeta1-42, J. of Neuroscience Research, Vol. 66, 2001, pp. 573-582				
/AMF/		SMITH et al., Amyloid Beta Deposition In Alzheimer Transgenic Mice is Associated With Oxidative Stress, J. of Neurochemistry, Vol. 70, No, 5, 1998 pp. 2212-2215				
/AMF/		STURCHLER-PIERRAT et al., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, PNAS, Vol. 94, Nov. 1997, pp. 13287-13292				
/AMF/	TAKEUCHI et al., Age-Related Amyloid Beta Deposition in Transgenic Mice Overexpressing Both Alzhei Mutant Presenilin 1 and Amyloid Beta Precursor Protein Swedish Mutant Is Not Associated with Global N Loss, Am. J. of Pathology, Vol. 157, No. 1, July 1, 2000, pp. 331-339					
		·				

		The second second	
Examiner	/Anne Marie Falk/	Date	07/23/2007
Signature	Mille Walle Laik	Considered	01123/2001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.